Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)

NCT03909724 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer
Metastasis

Interventions

DRUG: Sunitinib Malate
DRUG: TAS 102

Sponsor

Amsterdam UMC, location VUmc